J&J sews up 5 years of coronavirus vaccine supply in $480M-plus deal with Emergent

J&J and Maryland-based CDMO Emergent BioSolutions inked a five-year work order worth at least $480 million to help produce the New Jersey-based drugmaker's COVID-19 vaccine candidate, Emergent said in a release.